Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
Boston Scientific has enjoyed success in the cardiac device space, but it continues to look to gain market share elsewhere, ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Boston Scientific, an MD+DI Medtech Company of the Year finalist, announced positive three-year primary endpoint results over the weekend from the OPTION global clinical trial of its Watchman Flx left ...
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...
The U.S. Food and Drug Administration is warning patients and doctors about possible issues seen with Boston Scientific heart devices. The FDA issued alerts on Aug. 6 about the Marlboro-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results